BotB data

ATHN (South San Francisco) announced findings of three open-label Phase I trials in 32 patients, who received a total of 72 injections of the toxin, ranging from 100 to 2400 units. Doses greater than 900 showed efficacy in 70 percent of the treatments. No adverse effects were noted at any dose. ...